Premium
Pirfenidone photosensitization in patients with idiopathic pulmonary fibrosis: a case series
Author(s) -
Droitcourt C.,
Adamski H.,
Polat A.,
Polard E.,
Kerjouan M.,
Arnouat B.,
Le Garrec M.,
Oger E.,
Dupuy A.,
Jouneau S.
Publication year - 2018
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.16016
Subject(s) - pirfenidone , medicine , idiopathic pulmonary fibrosis , rash , adverse effect , dermatology , pulmonary fibrosis , fibrosis , disease , interstitial lung disease , lung , gastroenterology
The oral antifibrotic agent, pirfenidone (PFD), 5-methyl-l-phenyl-[1H]-pyridine, is used to treat idiopathic pulmonary fibrosis (IPF), a chronic and fatal lung disease. In trials, PFD reduces disease progression and decreases mortality. The most common side events of PFD are skin manifestations (25%), described as a photosensitivity or rash, but they are not well characterised (1) . This article is protected by copyright. All rights reserved.